Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14787747 | 1.00 | HSD17B10 (0.36) | HSD17B10TSHRTDP1MEN1THRB | |
| SCHEMBL680603 | 0.97 | — | — | |
| SCHEMBL28222184 | 0.97 | HSD17B10 (0.38) | HSD17B10TSHRTDP1ALDH1A1TP53 | |
| Water SCHEMBL28190788 | 0.94 | HSD17B10 (0.36) | HSD17B10TSHRTDP1ALDH1A1TP53 | |
| 1,2-Dichloroethane SCHEMBL28830085 | 0.87 | HSD17B10 (0.39) | HSD17B10TSHRTDP1MEN1THRB | |
| Propanol SCHEMBL28222183 | 0.86 | TSHR (0.44) | HSD17B10TSHRTDP1MEN1THRB | |
| SCHEMBL20461144 | 0.83 | — | — | |
| Methylene Chloride SCHEMBL27369702 | 0.83 | HSD17B10 (0.41) | HSD17B10TSHRTDP1MEN1THRB | |
| SCHEMBL20357702 | 0.83 | ALDH1A1 (0.41) | TSHRMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL20450717 | 0.83 | ALDH1A1 (0.41) | TSHRMEN1KMT2AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024469-A1 | VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS | THE UNIV OF MONTANA (US) | 2024-01-25 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-10179175-B2 | Isatoic anhydride derivatives and applications thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2019-01-15 | — | — | US | disclosed |
| EP-3148674-B1 | ABSORBENT SOLUTION CONTAINING A MIXTURE OF 1,2-BIS-(2-DIMETHYLAMINOETHOXY)-ETHANE AND 2-[2-(2- DIMETHYLAMINOETHOXY)-ETHOXY]-ETHANOL, AND METHOD FOR ELIMINATING ACID COMPOUNDS FROM A GAS EFFLUENT | IFP ENERGIES NOW (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-20180110862-A1 | ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE | 2018-04-26 | — | — | US | disclosed |
| US-9867883-B2 | Isatoic anhydride derivatives and applications thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170035893-A1 | ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE | 2017-02-09 | — | — | US | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179175-B2 | Isatoic anhydride derivatives and applications thereof | AASDHPPT, CA13, CA12 | HSD17B10 4348/4885TSHR 4459/4885TDP1 2667/4885 |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | HSD17B10 4216/4885TSHR 3418/4885TDP1 2204/4885 |
| US-20240024469-A1 | VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS | TLR7, TLR9, TLR8 | HSD17B10 3044/4885TSHR 943/4885TDP1 3056/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | HSD17B10 3733/4885TSHR 4023/4885TDP1 2507/4885 |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | GPR119, IAPP, LIPA | HSD17B10 676/4885TSHR 550/4885TDP1 3457/4885 |
| US-20180110862-A1 | ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF | AASDHPPT, CA13, CA12 | HSD17B10 4348/4885TSHR 4459/4885TDP1 2667/4885 |
| US-20170035893-A1 | ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF | AASDHPPT, CA13, CA12 | HSD17B10 4348/4885TSHR 4459/4885TDP1 2667/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | HSD17B10 166/4885TSHR 3525/4885TDP1 1615/4885 |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | IAPP, PNLIP, AMY2A | HSD17B10 1069/4885TSHR 1497/4885TDP1 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.